Tag Archives: Obamacare
Are US and Canadian Rx Policies Converging?
by Tom Norton
As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program. To say that this is a critical concern for the future [...]
Posted in Global, Guest Blog, Legal, Market Access, Strategy, healthcare Also tagged Affordable Care Act, Canada, essential health benefits, health insurance, HHS, Medicare Leave a comment
State Surprises as Obamacare Starts Up
by Tom Norton
This past week or so, with Obamacare’s start up less than a year away, we have been treated to several entertaining vignettes as the nation’s governors begin to wrestle with the realities of the new healthcare law.
Posted in Guest Blog, Legal, Strategy, healthcare, leadership Also tagged ACA, health exchanges, Health Reform, HHS, Kathleen Sebelius, Medicaid, Medicare, States Leave a comment
Questions About the 2013 Implementation of IPAB
by Tom Norton
With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun. Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th. A huge amount of activity, to be sure, but as stated, not surprising. That’s because the law [...]
Posted in FDA, Legal, Market Access, Regulatory, healthcare, pricing Also tagged Affordable Care Act, CMS, cost-cutting, government, HHS, IPAB, pricing Leave a comment
With the Election Decided, It's Full Speed Ahead on ObamaCare
by Tom Norton
With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare. Here are some of the key actions to anticipate between now and January 1, 2013.
Posted in FDA, Legal, Regulatory, Strategy, healthcare Also tagged Affordable Care Act, HHS, Medicare, Presidential election, Regulatory, US election 3 Comments

Despite Growing Momentum, Repeal of Medical Device Tax Faces Significant Hurdles